Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18705776 | 0.93 | SMYD3 (0.80) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL18706223 | 0.91 | SMYD3 (0.75) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL18705708 | 0.91 | SMYD3 (0.75) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL18705841 | 0.90 | SMYD3 (0.74) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL18738716 | 0.89 | SMYD3 (0.88) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL18738728 | 0.87 | SMYD3 (1.00) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL20781475 | 0.87 | SMYD3 (1.00) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL20781687 | 0.87 | SMYD3 (1.00) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL18706128 | 0.87 | SMYD3 (0.81) | SMYD3ALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL18738641 | 0.87 | SMYD3 (1.00) | SMYD3ALDH1A1HTTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | SMYD3 1/4885ALDH1A1 373/4885HTT 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.